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Introduction
The most appropriate approach to the management of early prostate cancer, that is disease limited to the prostate and draining lymph nodes, has yet to be defined. Conventionally, patients with early-stage disease have been treated by radical prostatectomy, radiotherapy or watchful waiting; the latter practice is particularly common in Scandinavia, whereas a very high proportion of patients in North America undergo radical surgery. In recent years, we have seen the introduction of endocrine therapy, medical or surgical castration and/or antiandrogen therapy at earlier disease stages than before [1] . In particular, there is now considerable interest in the use of adjuvant hormonal therapy, an additional treatment given after resection or destruction of all gross disease which is hoped to improve outcome, particularly survival outcome. This paper will discuss the current status of adjuvant hormonal therapies including orchiectomy, luteinizing hormone-releasing hormone (LH-RH) agonists and non-steroidal antiandrogens in both the surgical and radiotherapy settings.
Why Use Adjuvant Therapy after Radical Prostatectomy?
It is now well recognized that a significant proportion of men with early-stage prostate cancer experience local or systemic progression and/or die from the disease despite receiving therapies of primary curative intent and that this risk rises with increasing pathological stage [1] . For example, in a study of 721 men with clinically localized T1 or T2 (cT1-2) disease [2] , the most favourable outcome at 10 years with respect to progression (defined as an elevated postoperative prostate-specific antigen [PSA] 10.2 ng/ml, evidence of local recurrence or distant metastases) was seen in men with organ-confined disease, who had an 84.7% probability of remaining progression-free. This was significantly (p ^ 0.0001) better than in men with either focal or established capsular penetration (but negative seminal vesicles and negative lymph nodes) in whom the progression-free risk was 67.7 and 58.4%, respectively. For men with negative seminal vesicles and negative lymph nodes (n = 617), the presence of positive surgical margins also influenced the risk of progression, with a 10-year progression-free risk of 54.9% compared with 79.4% in those with negative margins (p ! 0.00001). The prognosis was particularly poor in men with seminal vesicle invasion or lymph node metastases. Of the former group, only 27% were free of disease at 10 years, whereas all patients with lymph node metastases had progressed within 10 years.
Similarly, Iselin and coworkers [3] have recently reported that the incidence of PSA failure (defined as a PSA 10.5 ng/ml) 5 years after radical perineal prostatectomy in 1,242 men with cT1-2N0M0 disease increased with increasing pathological stage (organ-confined disease 8%, specimen-confined disease 35%, positive surgical margins 65%; p = 0.001). Patients with organ-confined disease continued to have an excellent disease-free survival at 8 years.
Radical surgery is, therefore, not curative in many patients with early-stage disease. However, the use of neoadjuvant therapy does not appear to offer any additional benefit in this setting, even in patients with cT2a-T2b disease, probably due to residual foci of cancerous cells outside the surgical margin [4] . Adjuvant therapy may, nevertheless, have a role, although not all patients can be expected to benefit; for example, given the generally favourable prognosis for organ-confined disease, it is probably unreasonable to administer a treatment which may have a negative impact on quality of life to all of these men. The challenge, therefore, is to identify those subgroups for whom adjuvant therapy may be beneficial.
There are numerous studies describing prognostic factors for disease recurrence after radical prostatectomy, which may be of value in selecting those patients most likely to benefit from adjuvant therapy. These prognostic factors include the Gleason score, extent of capsular penetration, status of the surgical margins, seminal vesicle involvement and lymph node metastases [2, 3] . In particular, adjuvant therapy may be beneficial for patients who are found to have lymph node metastases or pT3 disease at surgery. In this latter group, the 10-year disease-free survival is approximately 50% [1] .
Adjuvant Therapy in Men with Lymph Node Metastases
The role of radical prostatectomy in patients who present with lymph node metastases is controversial. However, in a retrospective matched-pair comparison of radical prostatectomy with pelvic lymphadenectomy plus early orchiectomy and orchiectomy alone, Ghavamian and coworkers [5] showed that the removal of the prostate increased the chance of survival at 10 years; the combined approach improved both the 10-year tumour-specific survival (79 vs. 39%; hazard ratio [HR] 0.28; 95% confidence intervals [CI] 0.13-0.59; p ! 0.001) and overall survival (66 vs. 28%; HR 0.36; 95% CI 0.20-0.66; p ! 0.001) compared with orchiectomy alone. However, when matching included the preoperative PSA level, radical prostatectomy plus orchiectomy conferred a much smaller survival advantage, with a 5-year cause-specific survival of 79% compared with 63% with orchiectomy alone (HR 0.42; 95% CI 0.08-2.25; p = 0.19).
The Mayo Clinic has administered early adjuvant hormonal therapy after radical prostatectomy in patients with lymphatic spread for many years. In a retrospective study, Zincke and coworkers [6] reported that the 10-year probability of remaining free of progression (local or distant recurrence) for men who had received adjuvant hormonal therapy (orchiectomy and/or oral hormones with or without radiation) was significantly superior to that in men who underwent surgery alone with deferred androgen deprivation (76.4 vs. 24.3%; p ! 0.0001). However, this did not translate into a statistically significant survival advantage (p = 0.073) or to an increase in cancerspecific survival (80.1 vs. 71.4%; p 1 0.1). In a further retrospective study, the same group demonstrated that patients with diploid tumours who received adjuvant hormonal therapy had a significantly better cause-specific Wirth/Froehner 48.5%; p ! 0.002); no impact on survival was apparent before 10 years [7] . The results of these and other retrospective studies [8] suggest that combining radical prostatectomy and adjuvant androgen deprivation may improve long-term outcome in men with positive lymph nodes, as well as eliminating the possibility of local problems from the primary tumour. These results need confirming in a prospective study with a randomized design.
Adjuvant Therapy in Stage pT3 Disease
No studies of adjuvant therapy for patients with extracapsular extension at surgery have been completed. However, an interim analysis of an open, randomized controlled trial of adjuvant flutamide 250 mg three times daily, in which progression was defined as PSA, local or systemic failure, has shown that the antiandrogen significantly improved the progression-free survival at 4 years (90 vs. 69%; p = 0.0029) [9] . However, when patients in whom the only indicator of progression was an increase in PSA are excluded, the proportion of men with progression is low and similar in the two groups (flutamide 4/139, control 5/144).
The incidence of study withdrawal due to side effects in the flutamide group was disappointing, with 28/139 (20.1%) men discontinuing therapy (table 1). The predominant side effects were gynaecomastia (20.8%), nausea/vomiting (7.2%) and hepatic toxicity (2.9%); corresponding rates of these events in the control arm were 0, 1.4 and 0%, with only 1/144 (0.7%) withdrawing from the study. Further follow-up of the patients in this study is necessary to establish if adjuvant flutamide has a positive benefit with respect to survival.
Adjuvant Hormonal Therapy after Radiotherapy
Why Use Adjuvant Therapy after Radiotherapy? As in the surgical setting, outcome after radiotherapy correlates with clinical stage. In clinically localized disease, the 5-and 10-year survival for men with cT1 disease is about 75-85 and 55-80%, respectively; corresponding survival rates for cT2 disease are 55-80 and 45-65% [1] . Patients with cT3-4 disease have a poorer outcome, with a 5-year survival lower than 50%.
Radiotherapy and endocrine therapy may have an additive effect on cancer cells and, therefore, the initiation of adjuvant or neoadjuvant endocrine therapy may improve the outcome after radiotherapy. In general, as radiotherapy patients tend to have a higher clinical stage than radical prostatectomy patients, adjuvant therapy is expected to afford greater benefit after radiotherapy than after radical prostatectomy.
Prospective Studies of Adjuvant Therapy
To date, three prospective randomized studies have evaluated the benefits of adjuvant hormonal therapy after radiotherapy of curative intent [10] [11] [12] .
The Radiation Therapy Oncology Group (RTOG) protocol 85-31 was designed to prospectively assess the efficacy of an adjuvant LH-RH agonist after radiotherapy for stage C or D1 disease [10] . A total of 977 men scheduled for radiotherapy were enrolled in this study and randomized to either immediate hormonal therapy with goserelin acetate 3.6 mg/month, which was commenced during the last week of radiotherapy (n = 477), or to radiotherapy only with hormonal therapy administered only at the time of relapse (n = 468). The majority of enrolled patients (85%) had a Gleason score 66. Just over 25% of patients had positive lymph nodes; about 15% of men had previously undergone radical prostatectomy. Pretreatment prognostic factors were well balanced between the two groups.
Follow-up time in this study ranged from 0.23 to 8.82 years (median 4.5 years). Adjuvant therapy significantly improved both the local progression rate at 5 years (16 vs. 29%) and the disease-free survival (60 vs. 44%) (both p ! 0.0001). The analyses of disease-free survival, including PSA failure (cut-off either 1.5 or 4 ng/ml), and of the development of distant metastases also favoured the adjuvant arm (all p ! 0.0001). Overall survival did not differ significantly between the groups (75 vs. 71%; p = 0.52); however, when patients were subdivided according to Gleason score, adjuvant therapy did improve overall 5-year survival in the subgroup with a Gleason score of 8-10 (66 vs. 55%; p = 0.03) ( fig. 1 ). When prostatectomy patients were excluded from the analysis of patients with a Gleason score 8-10, the difference in overall survival between the adjuvant and control arms was even greater (p = 0.01). Follow-up is continuing in this study to establish whether the improved local control and disease-free survival seen in the adjuvant arm will ultimately prolong survival in patients with a Gleason score of 2-7.
In a second study, Granfors and coworkers [11] evaluated the impact of combined orchiectomy and external radiotherapy compared with radiotherapy alone, with androgen ablation given at relapse in men with T1-4NxM0 disease. The authors planned to enrol up to 400 men, but they terminated the study after an interim analysis in 91 men (radiotherapy plus orchiectomy 45, radiotherapy only 46), showing a high incidence of progression in the radiotherapy arm. Of the men enrolled, 39 (43%) had lymph node involvement.
After a median follow-up of 9.3 years (range 6.0-11.4 years), the mortality from any cause was 38% in the combined treatment group and 61% in the radiotherapy group (p = 0.02) (fig. 2) . The advantage for adjuvant therapy with respect to cause-specific mortality almost attained statistical significance (27 vs. 44%; p = 0.06). The difference between the treatment groups in both the overall and cause-specific mortality was mainly seen in men with positive lymph nodes (p ! 0.001 and p = 0.001, respectively). Adjuvant therapy also reduced the proportion of patients with local or distant failure (p = 0.005). However, when patients were subdivided according to the presence or absence of lymph node metastases, the benefits of adjuvant therapy on time to progression were confined to the subgroup with positive nodes.
The third prospective study of adjuvant therapy in the radiotherapy setting was conducted by the European Organization for Research and Treatment of Cancer (EORTC) and was reported by Bolla and associates [12] . This study involved 415 men with previously untreated prostate cancer without nodal involvement who were randomized to receive external pelvic irradiation alone (n = 208) or with adjuvant goserelin acetate 3.6 mg/month commenced immediately and continued for 3 years. Patients in this study had a poorer prognosis than those in the two trials described above; 85% had T3-4 disease and more than half had a pretreatment PSA 120 ng/ml.
With a median 45 months' follow-up, the KaplanMeier estimates for the 5-year overall survival were 79 and 62% in the adjuvant and control arms, respectively (p = 0.001) (fig. 3) ; for overall survival the HR was 0.50 (95% CI 0.33-0.76). These results need to be considered in the context of the lower than expected survival rate in the control arm, which implies that the patients had more advanced disease than stated [4] . Alternatively, patients may have been inadequately staged or had an unusually high rate of intercurrent deaths. For patients who survived 5 years, the disease-free rate was 85 and 48%, respectively (p ! 0.001) ( fig. 3 ). Adjuvant therapy also improved local control (HR 0.19; 95% CI 0.10-0.37; p ! 0.001). Treatment with an LH-RH agonist was not associated with an increase in grade 3 or 4 adverse events.
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Wirth/ Froehner   Fig. 3 . Disease-free and overall survival in men with locally advanced prostate cancer treated with radiotherapy with or without hormonal deprivation (n = 401). Adapted with permission from [12] . Non-steroidal antiandrogen therapy offers significant quality of life benefits over castration, particularly with respect to sexual activity, and is, therefore, of considerable interest as an adjunctive treatment in early prostate cancer. In this context, therapy will be long-term and the antiandrogen must be well tolerated; comparative data in other settings show that bicalutamide has a better tolerability profile than flutamide.
A large ongoing international programme is investigating the role of bicalutamide in early prostate cancer (T1-4NxM0) [13] . The programme comprises three randomized studies in different geographical areas (North America, Scandinavia and other areas, but predominantly Europe excluding Scandinavia), of similar design, in which bicalutamide 150 mg/day will be compared with placebo either as an adjuvant to therapy of primary curative intent (radical prostatectomy or radiotherapy) or as immediate hormonal therapy. Recruitment to the programme began in 1995 and is now complete, with a total patient sample of 8,113 [13] . Of the patients recruited in North America (n = 3,292), more than 80% had undergone radical surgery, compared with about 60% in the European study (n = 3,603) and !20% in Scandinavia (n = 1,218). These differences are an accurate reflection of routine clinical practice in the different geographical areas. There was also a difference between the geographical areas with respect to tumour stage, with more than 70% of patients in the North American trial having a tumour stage !T3 compared with about 60% in the other two studies. However, the randomization procedure has ensured that both the treatment groups are well balanced with respect to both demographic and prognostic characteristics [13] . It is anticipated that the results of this study, which is the largest ongoing prostate cancer trial in the world, will provide important information on the role of adjuvant antiandrogen therapy in early prostate cancer.
Conclusions
In conclusion, adjuvant hormonal therapy appears promising, particularly in the radiotherapy setting and also in certain patient subgroups following radical prostatectomy. However, many issues still need to be addressed. The patient subgroups who will benefit most from adjuvant therapy need to be defined. The long-term side effects of the different therapeutic modalities available for adjuvant therapy need to be compared as quality of life is particularly important in men with early-stage disease. Finally, it is important to demonstrate that adjuvant therapy confers a survival benefit. It is hoped that the ongoing bicalutamide early prostate cancer programme will answer some of these outstanding issues.
